Medtronic's Integrity coronary stent
This article was originally published in The Gray Sheet
Executive Summary
Firm launches its Integrity bare-metal coronary stent in the U.S. following PMA supplement approval, Medtronic announces Sept. 20. The device incorporates continuous sinusoid technology paired with the firm's MicroTrac delivery system to offer improved deliverability and conformability, the company explains. Continuous sinusoid technology enables the stent to be made from a single wire. The device received CE mark clearance in February and is already available outside the U.S. Medtronic also recently received CE mark clearance for its Resolute Integrity drug-eluting coronary stent (1"The Gray Sheet" Sept. 8, 2010)
You may also be interested in...
Medtronic's Resolute Integrity
Firm announces CE mark clearance and international roll-out of its Resolute Integrity zotarolimus-eluting coronary stent system on Aug. 30. Shipments will start the week of Sept. 6. The device incorporates the MicroTrac delivery system and continuous sinusoid technology to offer improved deliverability and conformability while retaining the same drug and BioLinx polymer of the original Resolute drug-eluting stent, the firm explains. Continuous sinusoid technology enables the stent to be made from a single wire. Medtronic notes it also will pursue U.S. approval
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.